PERFUSE: Non-Interventional Cohort Study of Patients Receiving Infliximab Biosimilar SB2: Results in Pediatric Patients

PERFUSE is a non-interventional study of 1233 patients [inflammatory rheumatic disease, n = 496; inflammatory bowel disease (IBD), n = 737] receiving infliximab (IFX) biosimilar SB2 therapy. This analysis describes response to treatment and persistence on SB2 for up to 12 months in pediatric IBD pat...

Descripción completa

Detalles Bibliográficos
Autores principales: Martinez-Vinson, Christine, Lemoine, Anaïs, Bouhnik, Yoram, Braithwaite, Ben, Fohlen-Weill, Audrey, Addison, Janet
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Original Articles: Gastroenterology: Inflammatory Bowel Disease
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10013152/
https://www.ncbi.nlm.nih.gov/pubmed/36729422
http://dx.doi.org/10.1097/MPG.0000000000003683

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10013152/
https://www.ncbi.nlm.nih.gov/pubmed/36729422
http://dx.doi.org/10.1097/MPG.0000000000003683

Ejemplares similares